Quality of life and response to treatment in cats with hypersomatotropism: the owners’ point of view

• Published in: Journal of feline medicine and surgery Vol. 24; no. 8; pp. e175 - e182
• Main Authors: Corsini, Andrea, Niessen, Stijn JM, Miceli, Diego D, Caney, Sarah, Zeugswetter, Florian K, Sieber-Ruckstuhl, Nadja S, Arenas, Carolina, Fleeman, Linda M, Leal, Rodolfo O, Battellino, Martina, Fracassi, Federico
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.08.2022
• Subjects: Acromegaly; Animals; Cabergoline - therapeutic use; Cat Diseases - drug therapy; Cats; Diabetes Mellitus - veterinary; Original; Quality of Life; Surveys and Questionnaires; hypophysectomy; survival time; insulin; radiation therapy; Acromegaly; diabetes mellitus; cabergoline
• ISSN: 1098-612X; 1532-2750; 1532-2750
• DOI: 10.1177/1098612X221098718

Objectives The aim of this study was to collect clinical information from owners of cats with hypersomatotropism (HS) distributed worldwide, assessing the impact of HS and its treatments on cats’ quality of life (QoL) and survival time. Methods A survey focused on clinical presentation, diagnostic procedures, treatments, cats’ QoL and disease progression was distributed worldwide to owners of cats with HS. The owner’s perception of the cats’ QoL before and after or during treatment was defined using a score ranging from 1 (poor) to 5 (excellent). Improvement following treatment (IFT) was quantified using a score ranging from 1 (absent) to 5 (obvious). Different treatment groups, including at least five cases, were compared. Results A total of 127 cats were included from at least 11 different countries. Among these, 120 (95%) were diabetic and 7 (5%) were not. Out of 120 diabetic cats, 55 (46%) were treated with insulin as a single treatment (INS). Other treatments were not mentioned to owners in 35/120 (29%) cases. The median QoL score at diagnosis was 2 (range 1–5) and improved after treatment in all groups. Cabergoline (4; range 1–5), radiotherapy (4; range 2–5) and hypophysectomy (5; range 4–5) showed better median IFT scores compared with INS (3; range 1–5) (P = 0.046, P <0.002 and P <0.0001, respectively). Hypophysectomy IFT proved superior to cabergoline (P = 0.047) and was equal to radiotherapy IFT (P = 0.32). No difference was found between cabergoline and radiotherapy IFT (P = 0.99). The median survival time (MST) was 24 months (range 0–75 months). Cats treated with INS showed shorter MST (22 months; range 0–69 months) compared with cats treated with causal treatments combined (36 months; range 3–75 months) (P = 0.04). Conclusions and relevance Not all cats with HS will have diabetes mellitus. Causal treatments seem associated with the greatest improvements in perceived cats’ QoL and survival; such treatments should therefore be discussed with owners. Cabergoline could be an effective alternative management option.